Prevention of high-dose-methotrexate neurotoxicity by adequate folinic acid rescue is possible even after central nervous system irradiation

Cohen, Ian J.

doi:10.1016/j.mehy.2006.04.074

Cited by 24 publications

(20 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…FA conjugates, which are covalently derivatized via its c-carboxyl moiety, can retain the high affinity ligand binding property of FA (K d * 10 -9 M), and the kinetics of cellular uptake of conjugated FA compounds by FRs is similar to that of free FA [14]. In addition, published data supported the contention that neurotoxicity can be prevented by adequate FA or folinic acid rescue even after very high doses of MTX [15][16][17].…”

Section: Introductionmentioning

confidence: 80%

Preparation, characterization, and in vitro release of folic acid-conjugated chitosan nanoparticles loaded with methotrexate for targeted delivery

Ji¹,

Wu²,

Liu³

et al. 2011

Polym. Bull.

View full text Add to dashboard Cite

To reduce the toxicity of methotrexate (MTX) and increase the targeting of nanoparticles, the MTX-loaded chitosan (CS) covalently bonded with folic acid (FA) nanoparticles were prepared, and sodium tripolyphosphate was used as the cross-linking agent. FA was successfully conjugated to CS confirmed by 1 H-NMR and Fourier transform infrared spectrometer (FT-IR). The prepared FA-CS nanoparticles were characterized by FT-IR spectroscopy to confirm the cross-linking reaction between FA-CS and cross-linking agent. X-ray diffraction was performed to reveal the crystalline nature of the drug after encapsulation. The average diameters of the nanoparticles ranged from 293.9 ± 24.2 to 401.5 ± 20.4 nm with a narrow particle size distribution. In vitro release pattern in phosphate buffer saline (pH 6.8) indicated that the characteristics of the MTX-loaded nanoparticles appeared to have an initial burst effect and followed by a slow, sustained drug release. FA or low molecular weight FA conjugate fragments were also released from the nanoparticles, which might have potential to reduce toxic effects of MTX within the body.

show abstract

Section: Introductionmentioning

confidence: 80%

Preparation, characterization, and in vitro release of folic acid-conjugated chitosan nanoparticles loaded with methotrexate for targeted delivery

Ji¹,

Wu²,

Liu³

et al. 2011

Polym. Bull.

View full text Add to dashboard Cite

show abstract

“…In addition, sulfur‐containing excitatory amino acids are derived from homocysteine, and it has been shown that these compounds are present in mammalian brain, predominantly in glial cells. These compounds activate excitatory amino acid receptors such as NMDA, which may lead to seizure and excitotoxicity and cell death (15, 27). In animal studies, MTX can increase the levels of adenosine, which is known to regulate cerebral blood flow and neuronal excitability.…”

Section: What Is New and Conclusionmentioning

confidence: 99%

Methotrexate-induced posterior reversible encephalopathy syndrome

Aradillas

Arora²,

Gasperino

2010

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

show abstract

“…Kinetics of cellular uptake of folate-conjugated compounds by folate receptors (FRs) is similar to free folate (35). In addition, folic acid can prevent nervous system toxicity even at very high doses of methotrexate (36)(37)(38). Folate receptor is a valuable therapeutic target which is strongly affected in different types of cancer.…”

Section: Introductionmentioning

confidence: 99%

Preparation, Characterization, and Optimization of Folic Acid-Chitosan-Methotrexate Core-Shell Nanoparticles by Box-Behnken Design for Tumor-Targeted Drug Delivery

et al. 2016

View full text Add to dashboard Cite

Abstract. The objective of this study was to investigate the combined influence of independent variables in the preparation of folic acid-chitosan-methotrexate nanoparticles (FA-Chi-MTX NPs). These NPs were designed and prepared for targeted drug delivery in tumor. The NPs of each batch were prepared by coaxial electrospray atomization method and evaluated for particle size (PS) and particle size distribution (PSD). The independent variables were selected to be concentration of FA-chitosan, ratio of shell solution flow rate to core solution flow rate, and applied voltage. The process design of experiments (DOE) was obtained with three factors in three levels by Design expert software. Box-Behnken design was used to select 15 batches of experiments randomly. The chemical structure of FA-chitosan was examined by FTIR. The NPs of each batch were collected separately, and morphologies of NPs were investigated by field emission scanning electron microscope (FE-SEM). The captured pictures of all batches were analyzed by ImageJ software. Mean PS and PSD were calculated for each batch. Polynomial equation was produced for each response. The FE-SEM results showed the mean diameter of the core-shell NPs was around 304 nm, and nearly 30% of the produced NPs are in the desirable range. Optimum formulations were selected. The validation of DOE optimization results showed errors around 2.5 and 2.3% for PS and PSD, respectively. Moreover, the feasibility of using prepared NPs to target tumor extracellular pH was shown, as drug release was greater in the pH of endosome (acidic medium). Finally, our results proved that FAChi-MTX NPs were active against the human epithelial cervical cancer (HeLa) cells.

show abstract

Prevention of high-dose-methotrexate neurotoxicity by adequate folinic acid rescue is possible even after central nervous system irradiation

Cited by 24 publications

References 38 publications

Preparation, characterization, and in vitro release of folic acid-conjugated chitosan nanoparticles loaded with methotrexate for targeted delivery

Preparation, characterization, and in vitro release of folic acid-conjugated chitosan nanoparticles loaded with methotrexate for targeted delivery

Methotrexate-induced posterior reversible encephalopathy syndrome

Preparation, Characterization, and Optimization of Folic Acid-Chitosan-Methotrexate Core-Shell Nanoparticles by Box-Behnken Design for Tumor-Targeted Drug Delivery

Contact Info

Product

Resources

About